banner轮播的第一个标题

Shanghai Biogerm Medical Technology Co., Ltd., a high-tech enterprise devoting to development and application of diagnostic reagents for infectious pathogens, is engaged in multiple fluorescent PCR diagnostic reagents, molecular diagnostic instruments, as well as pathogen sequencing services.

Biogerm has independently developed more than 400 varieties of nucleic acid test reagents, 12 varieties of nucleic acid extraction reagents and 5 types of instruments. In the COVID-19 pandemic, Novel Coronavirus (2019-nCoV) Nucleic Acid Detection Kit developed by Biogerm is one of the first approved for marketing by National Medical Products Administration (NMPA) in China.

In the future, Biogerm will hold fast to the original intention, strive to reinforce innovation and quality, and fulfill a comprehensive layout in the field of infectious pathogen diagnosis, to provide high-level integral solutions for the epidemic emergency detection, outpatient screening, accurate diagnosis for inpatients and identification of causes for difficult and severe diseases.